2. Overall Program Goals

3. Current Approaches

4. Treatment Resistance

5. Cellular Signaling

6. The PI3K/Akt/mTOR Pathway and Breast Cancer

7. Crosstalk Between ER and mTOR Signaling

8. mTOR Inhibitors in Breast Cancer

9. Temsirolimus + Letrozole: Clinical Data

10. Temsirolimus +/- Letrozole: First-line Advanced Breast Cancer

11. Temsirolimus +/- Letrozole: Adverse Events

12. Temsirolimus +/- Letrozole: Randomized Phase 3 Trial in First-Line Advanced Breast Cancer

13. RAD001: Phase 2 Neoadjuvant Everolimus in Breast Cancer

14. TAMRAD: Tamoxifen +/- Everolimus in Advanced Breast Cancer

15. TAMRAD: Results

16. TAMRAD: Results by Resistance

17. BOLERO-2: Trial Design

18. BOLERO-2: Baseline Characteristics

19. BOLERO-2: Prior Therapy

20. BOLERO-2 Primary Endpoint: PFS Central Assessment

21. BOLERO-2: Most Common Grade 3/4 Adverse Events

22. Other BOLERO Studies

23. Predictive Markers

24. PI3K Pathway Inhibitors in Clinical Trials

25. Targeting Endocrine Resistance in the Clinical Setting: Summary

26. Abbreviations

27. Abbreviations (cont)

28. Abbreviations (cont)

29. Abbreviations (cont)

30. References

31. References (cont)

32. References (cont)

33. References (cont)

34. References (cont)

35. References (cont)